A large retrospective cohort study suggested GLP1 receptor agonist use was not associated with a substantially increased risk (1.33 events per 10,000 person years) of thyroid cancer over a mean follow-up of 3.9 years [56]. Here, GLP1R is linked to thyroid gland carcinoma.